Matthew Perrone
The Associated Press
Washington, DC, United States
Contact Matthew
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Recent articles by Matthew:
FDA panel backs Pfizer’s low-dose COVID-19 vaccine for kids
WASHINGTON (AP) — U.S. health advisers have endorsed kid-size doses of Pfizer’s COVID-19 vaccine for young children. → Read More
FDA panel backs Pfizer’s low-dose COVID-19 vaccine for kids
WASHINGTON (AP) — The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as a panel of government advisers on Tuesday endorsed kid-size doses of PfizerR… → Read More
FDA panel backs Pfizer's low-dose COVID-19 vaccine for kids
WASHINGTON (AP) — The U.S. moved a step closer to expanding COVID-19 vaccinations for... → Read More
FDA panel backs Pfizer's low-dose COVID-19 vaccine for kids
WASHINGTON (AP) — The U.S. moved a step closer to expanding COVID-19 vaccinations for... → Read More
FDA advisers back Pfizer’s COVID-19 vaccine for young kids
A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer’s COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11. → Read More
FDA advisers back Pfizer’s COVID-19 vaccine for young kids
A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer’s COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11. → Read More
FDA advisers back Pfizer’s COVID-19 vaccine for young kids
WASHINGTON (AP) — A panel of U.S. health advisers on Tuesday endorsed kid-size doses of Pfizer’s COVID-19 vaccine, moving the U.S. closer to beginning vaccinations in children ages 5 to 11. A Food and Drug Administration advisory panel voted unanimously with one abstention that the vaccine’s benefits in preventing COVID-19 in that age group outweigh […] → Read More
FDA advisers review Pfizer’s COVID-19 vaccine for kids
Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether the shots are safe and effective for 5- to 11-year-olds. → Read More
FDA advisers review Pfizer’s COVID-19 vaccine for kids
U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective in young children → Read More
FDA advisers review Pfizer’s COVID-19 vaccine for kids
U.S. health advisers are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective in young children → Read More
FDA advisers review Pfizer’s COVID-19 vaccine for kids
WASHINGTON (AP) — Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether there’s enough evidence that the shots are safe and effective for 5- to 11-year-olds. A study of elementary schoolchildren found the Pfizer shots are nearly 91% effective at preventing symptomatic infection — even though […] → Read More
FDA advisers review Pfizer’s COVID-19 vaccine for kids
WASHINGTON (AP) — Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether there’s enough evidence that the shots are safe and effective for 5- to 11-year-olds. → Read More
FDA panel backs Pfizer’s low-dose COVID-19 vaccine for kids
WASHINGTON (AP) — The U.S. moved a step closer to expanding COVID-19 vaccinations for millions more children as a panel of government advisers on Tuesday endorsed kid-size doses of Pfizer's shots for 5- to 11-year-olds. → Read More
FDA advisers review Pfizer’s COVID-19 vaccine for kids
WASHINGTON (AP) — Kid-size doses of Pfizer’s COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether there’s enough evidence that the shots are safe and → Read More
FDA advisers review Pfizer's COVID-19 vaccine for kids
While children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds still have faced substantial illness -- including over 8,300 hospitalizations, about a third requiring intensive care, and nearly 100 deaths, FDA vaccine chief Dr. Peter Marks told the advisory panel. Also, "infections have caused many school closures and disrupted the education and socialization of… → Read More
FDA advisers review Pfizer's COVID-19 vaccine for kids
WASHINGTON (AP) — Kid-size doses of Pfizer's COVID-19 vaccine may be getting closer as government advisers on Tuesday began deliberating whether there's enough evidence that the shots are safe and effective for 5- to 11-year-olds. A study of elementary schoolchildren found the Pfizer shots are nearly 91% effective at preventing symptomatic infection -- even though the youngsters received just a… → Read More
Live: FDA advisers back Pfizer’s COVID-19 vaccine for kids
Advisers to the FDA are deliberating whether kid-size doses of Pfizer's COVID-19 vaccine are safe and effective in young children. If the FDA authorizes the shots, the CDC still must weigh in as well. That could happen next week. → Read More
FDA advisers back Pfizer’s COVID-19 vaccine for young kids
While children are at lower risk of severe COVID-19 than older people, 5- to 11-year-olds have faced substantial illness -- including over 8,300 hospitalizations. → Read More
FDA Says Pfizer COVID Vaccine Looks Effective for Young Kids
Federal health regulators said late Friday that kid-size doses of Pfizer’s COVID-19 vaccine appear highly effective at preventing symptomatic infections in elementary school children and caused no unexpected safety issues, as the U.S. weighs beginning vaccinations in youngsters. → Read More
Pfizer says COVID-19 vaccine more than 90% effective in kids
Pfizer says kid-size doses of its COVID-19 vaccine are safe and nearly 91% effective at preventing symptomatic infections in elementary schoolchildren → Read More